Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
This prospective, single-arm study is conducted to investigate the safety and efficacy of Sintilimab combined with hypofractionated radiotherapy in patients with microsatellite instability-high (MSI-H)/ DNA mismatch repair-deficient (dMMR) non-metastatic rectal cancer.
Anti-PD-1 Antibody|Radiotherapy|Rectal Cancer|MSI-H|Mmr Deficiency
DRUG: Sintilimab|RADIATION: Hypofractionated Radiotherapy
Adverse reaction, Adverse reaction after receiving treatment of Sintilimab combined with hypofractionated radiotherapy and perioperative complications, up to 10 weeks
Pathological response rate, Pathological response rate after treatment, 6-8 weeks after radiotherapy|Complete resection rate, Complete resection rate after treatment, 6-8 weeks after radiotherapy|Quality of life questionnaire, Quality of life during treatment, up to 10 weeks
The patients meet the inclusion criteria. After signing the informed consent, they are given radiotherapy 5Gyx5 and sintilimab 200mg ivgtt D1, D15, D29. Radical surgery is performed 6-8 weeks after radiotherapy.